Aeterna Zentaris Provides Update on Timing for Annual Meeting of Shareholders and Due Bill Redemption Date
May 29, 2024 18:35 ET
|
Aeterna Zentaris Inc
TORONTO, ONTARIO, May 29, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing...
Aeterna Zentaris Announces Details Regarding Transaction with Ceapro
May 17, 2024 08:00 ET
|
Aeterna Zentaris Inc
TORONTO, ON, May 17, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”) announces that it has finalized certain details regarding the previously...
Aeterna Zentaris Reports First Quarter 2024 Financial Results
May 14, 2024 18:00 ET
|
Aeterna Zentaris Inc
Company ended the quarter with $29.5 million in cashDETECT-trial recruitment completed; Company continues to expect the completion of the trial in the second quarter and top-line data in the third...
Aeterna Zentaris Announces Effective Date of Share Consolidation
May 01, 2024 07:55 ET
|
Aeterna Zentaris Inc
TORONTO, ON, May 01, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”) announces that it has filed articles of amendment to effect the previously...
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
March 28, 2024 07:55 ET
|
Aeterna Zentaris Inc
TORONTO and EDMONTON, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to announce...
Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
March 27, 2024 08:05 ET
|
Aeterna Zentaris Inc
- Company confirms successful completion of enrollment in the pivotal DETECT Phase 3 trial - Company ended the year with $34.0 million in cash, expected to fund operations through 2024 and into...
Aetherium Acquisition Corp Announces Postponement of Adjourned Special Meeting of Stockholders
March 19, 2024 09:00 ET
|
Aetherium Acquisition Corp.
~ Stockholders of Record as of February 9, 2024, are Eligible to Vote at Meeting ~ New York, March 19, 2024 (GLOBE NEWSWIRE) -- Aetherium Acquisition Corp (“Aetherium”) (NASDAQ:GMFI), a special...
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
March 12, 2024 14:10 ET
|
Aeterna Zentaris Inc
TORONTO and EDMONTON, March 12, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna”) and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to announce...
Generic Drugs market is projected to grow at a CAGR of 5.3% by 2034: Visiongain
March 07, 2024 12:02 ET
|
Visiongain Reports Ltd
Visiongain has published a new report Generic Drugs Market Report 2024-2034: Forecasts by Type (Simple Generics, Specialty Generics, Biosimilars), by Prescription Type (Prescription Generics,...
Aetherium Acquisition Corp Announces Postponement of Special Meeting of Stockholders
March 04, 2024 17:42 ET
|
Aetherium Acquisition Corp.
~ Stockholders of Record as of February 9, 2024, are Eligible to Vote at Meeting ~ New York, March 04, 2024 (GLOBE NEWSWIRE) -- Aetherium Acquisition Corp (“Aetherium”) (NASDAQ:GMFI), a special...